+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06189157

Open-label Phase IIIa Trial of MB-CART19.1 for Patients with Difficult-to-Treat Systemic Lupus Erythematosus

Led by Miltenyi Biomedicine GmbH · Updated on 2025-11-26

29

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying MB-CART19.1, an investigational treatment made of modified immune cells, in adults with refractory systemic lupus erythematosus SLE who have not responded to previous therapies. This phase IIIa open-label trial aims to determine the best dose and evaluate safety and effectiveness in patients with serious organ involvement due to SLE. The study is conducted across multiple centers and includes a small number of participants treated in dose groups. Participants will receive MB-CART19.1 cells in escalating doses starting from a low dose, with patients treated in groups of three. After each group, safety is reviewed before increasing the dose. The phase I part tests up to three dose levels, while phase IIa treats patients at the recommended dose to assess response and side effects. The treatment involves a single infusion of these modified T cells. During the study, participants will be closely monitored with frequent visits to check vital signs, lab tests, and the presence and activity of the infused cells. Follow-up occurs in three phases intense monitoring until 28 days post-infusion, ongoing assessments up to one year, and extended follow-up for another year or more, with some patients followed for up to 13 years. Researchers will measure remission rates, treatment response, immune system changes, and safety throughout the trial.

CONDITIONS

Brief Title

MB-CART19.1 in Refractory SLE

Research Team

C

Clinical Trial Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here